Faculty profile
Tricia Cottrell
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
Nature medicine · 2025
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.
Journal for immunotherapy of cancer · 2024
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance
Journal for ImmunoTherapy of Cancer · 2021 · first author
Latest funding
- $3,056,176
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
CIHR · 2023 · Co-investigator
- $1,224,000
Predictive biomarkers for adjuvant immune checkpoint inhibitor therapy in non-small cell lung cancer
CIHR · 2022 · Co-investigator
- $872,865
Immunophenotyping Malignant Pleural Mesothelioma: Identifying Predictive and Prognostic Biomarkers for Combinatorial Immunotherapy
CIHR · 2020 · Nominated PI
3 publications.
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
Reuss JE, Lee PK, Mehran RJ, Hu C, Ke S, Jamali A, Najjar M, Niknafs N, Wehr J, Oner E, Meng Q, Pereira G, Hosseini-Nami S, Sausen M, Zahurak M, Battafarano RJ, Hales RK, Friedberg J, Sepesi B, Deutsch JS, Cottrell T, Taube J, Illei PB, Smith KN, Pardoll DM, Tsao AS, Brahmer JR, Anagnostou V, Forde PM
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.
Lotze MT, Cottrell T, Bifulco C, Chow L, Cope L, Gnjatic S, Maecker HT, Yeong Poh Shen J
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance
Cottrell T, Zhang J, Zhang B, Kaunitz GJ, Burman P, Chan H-Y, Verde F, Hooper JE, Hammers H, Allaf ME
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Principal investigators: Hay, Annette; Bramson, Jonathan L; Delisle, Jean-Sébastien; Leblanc, Richard; Quizi, Jennifer L
Keywords: Biomanufacturing; Cancer; Cell Therapy; Clinical Trial; First-In-Human; Immunotherapy; Multiple Myeloma; Relapsed And Refractory; Synthetic Androgen Receptor
Predictive biomarkers for adjuvant immune checkpoint inhibitor therapy in non-small cell lung cancer
Principal investigators: Tsao, Ming-Sound; Goss, Glenwood D
Keywords: Adjuvant Therapy; Gene Expression Signature; Immune Checkpoint Inhibitor; Immunohistochemistry; Multiplex Immunostaining; Mutation; Non-Small Cell Lung Cancer; Pd-L1; Predictive Marker; Prognostic Marker
Immunophenotyping Malignant Pleural Mesothelioma: Identifying Predictive and Prognostic Biomarkers for Combinatorial Immunotherapy
Principal investigators: Cottrell, Tricia
Keywords: Biomarkers; Biostatistics; Immunotherapy; Malignant Pleural Mesothelioma; Multiplex Immunofluorescence; Quantitative Pathology; Spatial Computation; Tumour Microenvironment
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.